Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
— Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary…
Pharmaceuticals, Biotechnology and Life Sciences
— Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary…
– First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share…
– First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share…
Three oral presentations accepted on new clinical and preclinical data at the American Society of Gene and Cell Therapy (ASGCT)…
Gvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020 Gvoke HypoPen™ on track for planned launch in…
WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)–22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused…
– Significant recent progress achieved across pipeline of innovative Bicycle®–based therapies for oncology and beyond – Dosing underway in Phase…
Revenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $4.64…
End of Phase 2 meeting scheduled with the U.S. Food and Drug Administration (FDA) with feedback from the meeting expected…
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–Infiniti Research is the world’s leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed…